<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506675</url>
  </required_header>
  <id_info>
    <org_study_id>NEI-135</org_study_id>
    <secondary_id>2U10EY011751</secondary_id>
    <nct_id>NCT00506675</nct_id>
  </id_info>
  <brief_title>Combined Patching-Atropine for Residual Amblyopia</brief_title>
  <acronym>ATS11</acronym>
  <official_title>A Randomized Trial to Evaluate Combined Patching-Atropine for Residual Amblyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the effectiveness of treatment of residual amblyopia in
      children ages 3 to &lt; 10 years with visual acuity of 20/32 to 20/63 in the amblyopic eye. The
      study is a randomized clinical trial comparing intensive treatment (42 hours per week of
      patching plus daily atropine) with a control group that will have rapid weaning of existing
      treatment followed by spectacle correction only (if needed). The primary objective is to
      determine if this intensive treatment will improve visual acuity in patients with residual
      amblyopia.

      The primary outcome assessment is amblyopic eye visual acuity at 10 weeks.

      The primary analytic approach for the amblyopic eye acuity will be a treatment group
      comparison of the proportion of patients with at least two lines of visual acuity
      improvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amblyopia is the most common cause of monocular visual impairment in both children and young
      and middle-aged adults. Both patching and atropine are accepted treatment modalities for the
      management of moderate amblyopia in children. Despite best efforts with conventional
      treatment, some patients fail to achieve normal visual acuity in the amblyopic eye. In a
      randomized trial conducted by PEDIG comparing atropine versus patching in 3 to 6 year olds
      with moderate amblyopia (ATS1), 261 of 402 patients (65%) had amblyopic eye visual acuity of
      20/32 or worse after 6 months of treatment with patching or atropine. Beyond 6 months,
      treatment was at investigator discretion, and two years after randomization, 181 of 363
      children (50%) still had amblyopic eye visual acuity of 20/32 or worse. In a randomized trial
      conducted by PEDIG comparing patching regimens, 129 of 181 patients with moderate amblyopia
      (71%) and 145 of 157 patients with severe amblyopia (92%) had amblyopic eye visual acuity of
      20/32 or worse after 4 months of occlusion therapy. Many patients receive treatment beyond 6
      months but still fail to achieve normal visual acuity in the amblyopic eye. It is unknown
      whether an intensive &quot;final push&quot; of combined treatment with daily patching and atropine will
      improve visual acuity in these patients. Although some clinicians prescribe simultaneous
      patching and atropine for selected patients, there are no published reports of its
      effectiveness. Also, we are not aware of reports of response to treatment of residual
      amblyopia.

      The study has been designed as a simple trial that, other than the type of amblyopia therapy
      being determined through the randomization process, approximates standard clinical practice.
      Patients will be randomized to one of two treatment regimens:

        -  Intensive treatment: 42 hours per week of patching combined with daily atropine (1%)

        -  Control group: Weaning of the current treatment (two hours of daily patching for
           patients currently using patching and once weekly atropine for patients currently using
           atropine) for 4 weeks, then no treatment other than spectacles (if needed).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment and infeasibility of ever reaching the necessary sample size
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of Amblyopic Eye Visual Acuity at 10 Weeks</measure>
    <time_frame>10 Weeks</time_frame>
    <description>Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to &lt;7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to &lt;10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (SD) Distribution of Visual Acuity at 10 Weeks</measure>
    <time_frame>10 Weeks</time_frame>
    <description>Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to &lt;7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to &lt;10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of Amblyopic Eye Visual Acuity Change From Baseline to 10 Weeks</measure>
    <time_frame>baseline to 10 Weeks</time_frame>
    <description>Change in logMAR from baseline to 10 weeks was calculated, with positive difference indicating improvement. Note one logMAR line = 5 letters or one Snellen line equivalent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (SD) Change in Visual Acuity in the Amblyopic Eye at the 10 Week Primary Outcome Exam</measure>
    <time_frame>baseline to 10 Weeks</time_frame>
    <description>Change in logMAR from baseline to 10 weeks was calculated, with positive difference indicating improvement. Note one logMAR line = 5 letters or one Snellen line equivalent.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Amblyopia</condition>
  <arm_group>
    <arm_group_label>Intensive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>42 hours per week of patching combined with atropine (1%) once daily in the sound eye, with spectacle correction (if needed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Weaning</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For patients currently patching, reduce patching to two hours daily for four weeks, then no treatment thereafter except spectacle correction (if needed). For patients currently using atropine, reduce atropine to once weekly for 4 weeks, then no treatment thereafter except spectacle correction (if needed)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Patching</intervention_name>
    <description>42 hours per week of patching</description>
    <arm_group_label>Intensive</arm_group_label>
    <other_name>Coverlet, 3M Opticlude, Ortopad®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine</intervention_name>
    <description>daily atropine (1%)</description>
    <arm_group_label>Intensive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Patching</intervention_name>
    <description>two hours of daily patching for 4 weeks, then no treatment</description>
    <arm_group_label>Weaning</arm_group_label>
    <other_name>Coverlet, 3M Opticlude, Ortopad®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine</intervention_name>
    <description>once weekly atropine for 4 weeks, then no treatment</description>
    <arm_group_label>Weaning</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 3 to &lt; 10 years

          -  Amblyopia associated with strabismus, anisometropia, or both

          -  Visual acuity in the amblyopic eye between 20/32 and 20/63 inclusive

          -  Visual acuity in the sound eye 20/32 or better and inter-eye acuity difference &gt;= 2
             logMAR lines

          -  Current/previous treatment with patching and/or atropine subject to the following
             stipulations:

               -  No simultaneous treatment with patching and atropine in the past 6 months

               -  No prior use of atropine in combination with the sound eye spectacle lens reduced
                  by more than 1.50 D

               -  Maximum level of any previous treatment:

                    -  Patching: up to 42 hours per week (averaging 6 hours daily)

                    -  Atropine: up to once daily

               -  Current treatment with 42 hours per week patching or daily atropine

          -  No improvement in best-corrected amblyopic eye visual acuity between two consecutive
             visits at least 6 weeks apart using the same testing method and optimal spectacle
             correction (if needed), with no improvement defined as follows:

               -  No lines of improvement

               -  For patients tested using E-ETDRS, letter score that is no more than 4 letters
                  improved

          -  Wearing spectacles with optimal correction (if applicable)

          -  Investigator ready to wean or stop treatment

        Exclusion Criteria:

          -  Current vision therapy or orthoptics

          -  Ocular cause for reduced visual acuity

          -  Prior intraocular or refractive surgery

          -  Strabismus surgery planned within 10 weeks

          -  Known allergy to atropine or other cycloplegic drugs

          -  Known skin reactions to patch or bandage adhesives

          -  Down Syndrome present
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David K. Wallace, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University Eye Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Pediatric Eye Disease Investigator Group (PEDIG) Writing Committee, Wallace DK, Kraker RT, Beck RW, Cotter SA, Davis PL, Holmes JM, Repka MX, Suh DW. Randomized trial to evaluate combined patching and atropine for residual amblyopia. Arch Ophthalmol. 2011 Jul;129(7):960-2. doi: 10.1001/archophthalmol.2011.174.</citation>
    <PMID>21746992</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2007</study_first_submitted>
  <study_first_submitted_qc>July 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <results_first_submitted>September 14, 2010</results_first_submitted>
  <results_first_submitted_qc>February 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 23, 2011</results_first_posted>
  <last_update_submitted>July 6, 2016</last_update_submitted>
  <last_update_submitted_qc>July 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jaeb Center for Health Research</investigator_affiliation>
    <investigator_full_name>Ray Kraker</investigator_full_name>
    <investigator_title>Director, PEDIG Coordinating Center</investigator_title>
  </responsible_party>
  <keyword>Amblyopia</keyword>
  <keyword>Atropine</keyword>
  <keyword>Patching</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amblyopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between October 2007 and March 2009, 27 subjects were randomized to the intensive group and 28 randomized to the weaning group.</recruitment_details>
      <pre_assignment_details>Eligible subjects were aged 3-&lt;10 with strabismic and/or anisometropic amblyopia, best-corrected amblyopic eye acuity of 20/32 to 20/63, interocular acuity difference greater than or equal to 2 lines, and no improvement in amblyopic eye acuity between 2 consecutive visits at least 6 weeks apart.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intensive</title>
          <description>6 hours daily patching combined with daily atropine</description>
        </group>
        <group group_id="P2">
          <title>Weaning</title>
          <description>For patients currently patching, a reduction of current treatment for 4 weeks with 2 hours daily patching or once weekly atropine followed by spectacles alone if needed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intensive</title>
          <description>6 hours daily patching combined with daily atropine</description>
        </group>
        <group group_id="B2">
          <title>Weaning</title>
          <description>For patients currently patching, a reduction of current treatment for 4 weeks with 2 hours daily patching or once weekly atropine followed by spectacles alone if needed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.9" spread="1.1"/>
                    <measurement group_id="B2" value="6.9" spread="1.3"/>
                    <measurement group_id="B3" value="6.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Age at Enrollment in Years</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>3 to &lt; 7 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 to &lt; 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cause of Amblyopia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Strabismus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anisometropia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strabismus and Anisometropia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Treatment for Amblyopia at Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Patching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atropine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Distance Visual Acuity in Amblyopic Eye</title>
          <description>Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to &lt;7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to &lt;10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>20/63 (0.54 to 0.46 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/50 (0.44 to 0.36 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/40 (0.34 to 0.26 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/32 (0.24 to 0.16 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Distance Visual Acuity in Fellow Eye</title>
          <description>Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to &lt;7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to &lt;10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>20/32 (0.24 to 0.16 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/25 (0.14 to 0.06 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/20 (0.04 to -0.04 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/16 (-0.06 to -0.14 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Refractive Error in Amblyopic Eye (spherical equivalent/diopters)</title>
          <description>Spherical equivalent in diopters defined from cycloplegic refraction as sphere plus half the cylinder value</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 0.00D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to &lt; +1.00 D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>+1.00 to &lt; +2.00D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>+2.00 to &lt; +3.00D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>+3.00 to &lt; +4.00D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>greater than or equal to +4.00D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Refractive Error in Fellow Eye</title>
          <description>Spherical equivalent in diopters defined from cycloplegic refraction as sphere plus half the cylinder value</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 0.00D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 to &lt; +1.00D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>+1.00 to &lt; +2.00D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>+2.00 to &lt; +3.00D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>+3.00 to &lt; +4.00D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>greater than or equal to +4.00D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean (SD) Intereye Acuity Difference</title>
          <description>The difference between eyes in logMAR acuity was calculated with positive values indicating sound eye better. One letter = .02 logMAR, .1 logMAR = 5 letters or one line of visual acuity.</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.33" spread="0.11"/>
                    <measurement group_id="B2" value="0.31" spread="0.10"/>
                    <measurement group_id="B3" value="0.32" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean (SD) Distance Visual Acuity in Fellow Eye</title>
          <description>Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to &lt;7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to &lt;10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.02" spread="0.09"/>
                    <measurement group_id="B2" value="0.03" spread="0.10"/>
                    <measurement group_id="B3" value="0.03" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean (SD) Spherical Equivalent Refractive Error in Amblyopic Eye</title>
          <description>Spherical equivalent in diopters defined from cycloplegic refraction as sphere plus half the cylinder value</description>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.39" spread="2.33"/>
                    <measurement group_id="B2" value="4.24" spread="2.15"/>
                    <measurement group_id="B3" value="4.81" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean (SD) Spherical Equivalent Refractive Error in Fellow Eye</title>
          <description>Spherical equivalent in diopters defined from cycloplegic refraction as sphere plus half the cylinder value</description>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.46" spread="2.38"/>
                    <measurement group_id="B2" value="3.29" spread="1.90"/>
                    <measurement group_id="B3" value="3.37" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean (SD) Distance Visual Acuity in Amblyopic Eye</title>
          <description>Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to &lt;7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to &lt;10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.35" spread="0.09"/>
                    <measurement group_id="B2" value="0.34" spread="0.08"/>
                    <measurement group_id="B3" value="0.35" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Distribution of Amblyopic Eye Visual Acuity at 10 Weeks</title>
        <description>Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to &lt;7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to &lt;10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).</description>
        <time_frame>10 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive</title>
            <description>6 hours daily patching combined with daily atropine</description>
          </group>
          <group group_id="O2">
            <title>Weaning</title>
            <description>For patients currently patching, a reduction of current treatment for 4 weeks with 2 hours daily patching or once weekly atropine followed by spectacles alone if needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Amblyopic Eye Visual Acuity at 10 Weeks</title>
          <description>Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to &lt;7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to &lt;10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>20/125 (0.84 to 0.76 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/100 (0.74 to 0.66 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/80 (0.64 to 0.56 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/63 (0.54 to 0.46 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/50 (0.44 to 0.36 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/40 (0.34 to 0.26 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/32 (0.24 to 0.16 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/25 (0.14 to 0.06 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/20 (0.04 to -0.04 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/16 (-0.16 to -0.24 logMAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean (SD) Distribution of Visual Acuity at 10 Weeks</title>
        <description>Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to &lt;7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to &lt;10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).</description>
        <time_frame>10 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive</title>
            <description>6 hours daily patching combined with daily atropine</description>
          </group>
          <group group_id="O2">
            <title>Weaning</title>
            <description>For patients currently patching, a reduction of current treatment for 4 weeks with 2 hours daily patching or once weekly atropine followed by spectacles alone if needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean (SD) Distribution of Visual Acuity at 10 Weeks</title>
          <description>Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to &lt;7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to &lt;10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.10"/>
                    <measurement group_id="O2" value="0.29" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Distribution of Amblyopic Eye Visual Acuity Change From Baseline to 10 Weeks</title>
        <description>Change in logMAR from baseline to 10 weeks was calculated, with positive difference indicating improvement. Note one logMAR line = 5 letters or one Snellen line equivalent.</description>
        <time_frame>baseline to 10 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive</title>
            <description>6 hours daily patching combined with daily atropine</description>
          </group>
          <group group_id="O2">
            <title>Weaning</title>
            <description>For patients currently patching, a reduction of current treatment for 4 weeks with 2 hours daily patching or once weekly atropine followed by spectacles alone if needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Amblyopic Eye Visual Acuity Change From Baseline to 10 Weeks</title>
          <description>Change in logMAR from baseline to 10 weeks was calculated, with positive difference indicating improvement. Note one logMAR line = 5 letters or one Snellen line equivalent.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>greater than or equal to 3 lines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 to &lt; 3 lines worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 to &lt; 2 lines worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 1 logMAR line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 to &lt; 2 lines better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 to &lt; 3 lines better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>greater than or equal to 3 lines better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean (SD) Change in Visual Acuity in the Amblyopic Eye at the 10 Week Primary Outcome Exam</title>
        <description>Change in logMAR from baseline to 10 weeks was calculated, with positive difference indicating improvement. Note one logMAR line = 5 letters or one Snellen line equivalent.</description>
        <time_frame>baseline to 10 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive</title>
            <description>6 hours daily patching combined with daily atropine</description>
          </group>
          <group group_id="O2">
            <title>Weaning</title>
            <description>For patients currently patching, a reduction of current treatment for 4 weeks with 2 hours daily patching or once weekly atropine followed by spectacles alone if needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean (SD) Change in Visual Acuity in the Amblyopic Eye at the 10 Week Primary Outcome Exam</title>
          <description>Change in logMAR from baseline to 10 weeks was calculated, with positive difference indicating improvement. Note one logMAR line = 5 letters or one Snellen line equivalent.</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.056" spread="0.096"/>
                    <measurement group_id="O2" value="0.053" spread="0.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intensive</title>
          <description>6 hours daily patching combined with daily atropine</description>
        </group>
        <group group_id="E2">
          <title>Weaning</title>
          <description>For patients currently patching, a reduction of current treatment for 4 weeks with 2 hours daily patching or once weekly atropine followed by spectacles alone if needed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Light sensitivity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This trial was stopped after 18 months due to inadequate recruitment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Raymond Kraker, MSPH</name_or_title>
      <organization>Jaeb Center for Health Research</organization>
      <phone>813-975-8690</phone>
      <email>pedig@jaeb.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

